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Abstract
Background: The accountability for reasonableness (A4R) framework defines 4 conditions for legitimate healthcare 
coverage decision processes: Relevance, Publicity, Appeals, and Enforcement. The aim of this study was to reflect on how 
the diverse features of decision-making processes can be aligned with A4R conditions to guide decision-making towards 
legitimacy. Rare disease and regenerative therapies (RDRTs) pose special decision-making challenges and offer therefore 
a useful case study. 
Methods: Features operationalizing each A4R condition as well as three different approaches to address these features 
(cost-per-QALY-focused and multicriteria-based) were defined and organized into a matrix. Seven experts explored these 
features during a panel run under the Chatham House Rule and provided general and RDRT-specific recommendations. 
Responses were analyzed to identify converging and diverging recommendations.
Results: Regarding Relevance, recommendations included supporting deliberation, stakeholder participation and 
grounding coverage decision criteria in normative and societal objectives. Thirteen of 17 proposed decision criteria were 
recommended by a majority of panelists. The usefulness of universal cost-effectiveness thresholds to inform allocative 
efficiency was challenged, particularly in the RDRT context. RDRTs raise specific issues that need to be considered; 
however, rarity should be viewed in relation to other aspects, such as disease severity and budget impact. Regarding 
Publicity, panelists recommended transparency about the values underlying a decision and value judgements used in 
selecting evidence. For Appeals, recommendations included a life-cycle approach with clear provisions for re-evaluations. 
For Enforcement, external quality reviews of decisions were recommended. 
Conclusion: Moving coverage decision-making processes towards enhanced legitimacy in general and in the RDRT 
context involves designing and refining approaches to support participation and deliberation, enhancing transparency, 
and allowing explicit consideration of multiple decision criteria that reflect normative and societal objectives.
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Analysis
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Introduction
The debate on how best to support priority setting decisions 
in healthcare has accelerated in recent years due to, in part, a 
surge in technological innovation (eg, gene therapies), which 
often focus on previously untreatable, rare diseases (RDs), as 
well as to economic pressures. A central aspect of the debate 
is the notion of the legitimacy of the decision. The Oxford 
dictionary provides 2 definitions of legitimacy1: “conformity 
to the law or to rules” and “ability to be defended with logic 
or justification,” highlighting both the procedural as well as 
the substantive aspects of legitimacy.2,3 Daniels frames the 
legitimacy problem as the question under which conditions 
the moral authority of those who make limit-setting decisions 
should be accepted as legitimate.4 In response, Daniels 
and his coworkers have developed the accountability for 
reasonableness (A4R) framework, which defines 4 conditions 
that can enhance legitimacy and help stakeholders develop a 
mutual basis for decision-making5:
• Relevance (originally termed ‘reasonableness’ 
condition6): As the shared goal of the deliberation is 
meeting population health needs while taking into 
account resource limitations, decisions must be based on 
reasons that can be accepted to be relevant to this goal 
by all ‘fair-minded’ stakeholders, that is, those who are 
affected by the decision and who are willing to work 
together on the basis of reason.4,6,7 
• Publicity: Requires openness and transparency with 
regards to the decision itself and the reasons behind 
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Implications for policy makers
Using the accountability for reasonableness (A4R) as a conceptual framework, this study has explored how to move coverage decision-making 
processes towards enhanced A4R. 
• A key recommendation for meeting the A4R Relevance condition was to ground the criteria for healthcare coverage decisions in the legal/
constitutional framework and normative (ethical) foundations. 
• The importance of stakeholder involvement was highlighted and a reflective multicriteria-based approach was recommended to facilitate 
incorporation of diverse stakeholder perspectives, particularly those of patients in the rare disease (RD) context. 
• Since diverse stakeholders may justifiably disagree on how to balance different, and often conflicting, decision goals, a key recommendation was 
to create conditions during committee meetings that foster deliberation. 
• Additional recommendations included being fully transparent about the uncertainties surrounding a decision and, in that regard, further 
developing the art of effective and accurate public communication. 
Implications for the public
Making decisions on whether a new treatment should be covered by the health system is difficult, especially when it comes to therapies for rare 
diseases (RDs) and complex new types of treatments, such as gene therapy. In order to be legitimate, these decisions should be: (1) based on relevant 
reasons, (2) transparent with respect to all factors that were considered, (3) revisable in light of new evidence or arguments, and (4) there should 
be mechanisms to enforce these conditions. We discussed and explored systematically what can be recommended for designing decision-making 
processes that best align with each of these conditions with the goal of ensuring that healthcare coverage decisions are reasonable and fair.
Key Messages 
it.4,6-8 Daniels7: “There must be no secrets where justice 
is involved, for people should not be expected to accept 
decisions that affect their well-being unless they are aware 
of the grounds for those decisions.” 
• Revisability (originally termed ‘appeals condition’6): 
Requires the establishment of mechanisms through 
which stakeholders can appeal the decision (and it can be 
revised) on the basis of new evidence or arguments that 
were originally not duly considered.4,6,7
• Enforcement: Refers to enforcement of the other three 
conditions through voluntary (private) mechanisms or 
through public regulation.9
The A4R approach proposes a procedural framework for 
making limit-setting decisions in healthcare under resource 
constrains. It recognizes that stakeholders are likely to agree on 
a fair process, but may justifiably disagree about the range and 
relative importance of different values in decision-making.5 
The lack of guidance regarding the ‘Relevance’ condition, 
ie, how to ensure that decision criteria are reasonable and 
relevant to stakeholders, has been one of the major criticisms 
of the A4R framework.10-12 Indeed, the recent debate on how 
to embed health technology assessment (HTA) into A4R 
to support coverage decision-making has mainly evolved 
around ‘Relevance.’13 Baltussen et al14 stated that to further 
legitimacy and perceived fairness of decisions, rather than 
using generic, pre-established decision criteria, the full range 
of societal values relevant to a particular decision needs to be 
identified in a process that involves diverse stakeholders.14 
According to Daniels and colleagues, to be truly relevant 
and useful to decision-makers, HTA needs to be expanded 
beyond efficacy, safety and cost-effectiveness to address 
ethical questions, including, but not limited to, the trade-off 
between efficiency and equity, which needs to be addressed 
through a deliberative process.8,13
Different approaches to coverage decision-making may 
have distinct implications for meeting A4R conditions for 
legitimacy. Some current HTA processes rely on the cost 
per quality-adjusted life-year (QALY) concept as a guiding 
principle for resource allocation, with the goal of selecting 
interventions that will maximize aggregated population 
health, conceptualized as the sum of QALYs across 
individuals, for a given level of resources.15 The incremental 
cost-effectiveness ratio (‘cost/QALY’), however, is not the sole 
basis for decisions; other factors (eg, the innovative nature of 
the technology16) are usually also considered. 
The principal advantage of the use of QALYs is that it 
represents a generic measure of health which can be used 
across therapeutic areas. However, three principal ethical 
concerns have been raised with respect to resource allocation17: 
failure to give priority to those who are worst off (in terms of 
health or social standing); potential for discrimination against 
patients with disabilities and comorbidities who, when 
receiving the same intervention, will likely incur a smaller 
QALY gain than patients not affected by other conditions; and 
failure to account for qualitative differences in outcomes (eg, 
life extension vs quality of life improvement). Additionally, 
it can be debated whose utilities (ie, QALY weights) should 
be employed, those of patients, health experts or the general 
public.17 
Over the last decade, various multicriteria approaches for 
measuring the value of healthcare interventions and supporting 
coverage decision-making have also been developed.18-21 
These involve explicit consideration of multiple decision 
criteria, defined in relation to the objective of the decision and 
structured by applying multicriteria methodology.22 These 
approaches have the potential of consistently incorporating a 
broader range of criteria that stakeholders might find relevant 
for a given decision problem in line with their individual 
value systems and perspectives.23-25
While implementation of the A4R framework in current 
practice of health technology coverage decision-making 
has been examined,26-30 a fundamental understanding of 
the features that would be considered most conducive to a 
legitimate process should advance the debate and provide 
guidance for the development of methods, frameworks 
and approaches best suited to move towards that goal. In 
particular, approaches to help HTA processes address the 
tension between the goals of meeting individual patient needs, 
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serving the whole population equitably, and ensuring health 
system sustainability, need to be attended to and further 
explored.31,32 Striking a balance between these goals can 
become particularly challenging when appraising treatments 
for RDs and regenerative therapies (RTs) (such as, for example, 
orphan medicines and gene or cell therapies) due to high 
unmet needs, small patient populations and the often complex 
and high-cost nature of these treatments.25,33-35 In addition, 
assessing these therapies can be challenging due to specific 
issues in clinical evidence development, including small and 
often heterogeneous trial populations (with possibly varying 
disease classifications), lack of disease-modifying comparator 
therapies, and uncertainty about long-term outcomes.25,33-37 
For these reasons, RDs and RTs provide a highly relevant case 
study for developing guidance on legitimate HTA approaches. 
Using A4R framework as a reference, the objective of this 
study was to reflect on how the diverse features of decision-
making processes can best be aligned with conditions 
that promote A4R (Relevance, Publicity, Appeals, and 
Enforcement) to guide healthcare coverage decision-making 
towards enhanced legitimacy, in general, and within the 
specific context of RDs and RTs. 
Methods
HTA thought leaders explored and discussed during a 
panel session on how best to address the 4 A4R conditions 
for legitimacy and provided pertinent recommendations, 
in general, and within the specific context of RDs and RTs. 
For this purpose, a tool, the Legitimacy Exploration Matrix 
(LEM), was developed for this study and provided to the 
panelists to support their reflection and discussion on how 
to best align with the A4R conditions in coverage decision-
making. Panelists’ comments and recommendations were 
collected, analyzed and synthesized.
The Legitimacy Exploration Matrix
The LEM was developed to be used as a platform to support 
reflection and discussion during the panel session. Specific 
features that operationalize the 4 A4R conditions in decision-
making processes were defined and organized in the matrix 
by the A4R condition to which they pertain. Identification 
of these features was supported by a review of the literature 
on the requirements for legitimate and accountable decision-
making processes,4-10,38 including the A4R framework and 
its implementation in HTA processes.8,13,14,26-28,30,39-42 (Please 
refer to Supplementary file 1 for search strategies). A total 
of 34 features for operationalizing the A4R conditions were 
thus defined: 26 features for the A4R Relevance condition 
(including 19 features related to decision criteria, 3 to 
evidence and 4 to deliberation), 3 for the Publicity condition, 
2 for the Appeal condition, and 3 for the Enforcement (or 
Implementation) condition. (A condensed version of the LEM 
is available in Tables 1 to 4, the complete LEM is available as 
Supplementary file 1 – Appendix 1).
For each feature, specific questions were developed to 
further clarify the concept covered and collect targeted 
recommendations from the panelists. For example, for 
Understandability of the reasoning behind decisions (a feature 
for operationalizing the Publicity condition), the question 
was: What could be recommended to facilitate making explicit 
the reasons leading to the decision and understandable to 
stakeholders, including the public?
Defining features for operationalizing the Relevance 
condition required defining potential decision criteria. 
In order to ensure that a wide range of potential criteria 
would be included to be discussed during the panel session 
a systematic review was carried out to identify published 
multicriteria frameworks that have been proposed to be 
applicable to interventions targeting RDs (see Supplementary 
file 1 for search strategies- Appendix 2). The rationale for this 
approach was that these are generally the most comprehensive 
decision frameworks (up to 20-21 criteria) and include 
criteria that are proposed to be relevant for the specific 
context of RDs and RTs. Seven multicriteria frameworks 
were thus identified23,25,43-47 and the decision criteria that 
each of them proposed extracted and matched in tabular 
format (see Supplementary file 1 – Appendix 3). From this 
list of proposed criteria, those were included in the LEM that 
were featured in at least two of these frameworks, unless the 
rationale offered for the proposed criterion (by the authors 
of the respective framework) was based on price justification 
alone (eg, manufacturing complexity).
To explore during the panel session a range of possibilities 
by which each feature could be addressed, three general 
approaches to decision-making (‘archetypes’) were defined 
in the LEM5,15,23-25,31,41,48-56: (1) The classical cost-effectiveness 
approach, being rooted in a variant of utilitarian thought, 
strives to maximize aggregated population health using 
the cost-per-QALY ratio as a pre-established, dominant 
decision criterion. Under this archetype, the decision-making 
committee’s deliberation focuses on interpreting the cost-per-
QALY model and its output, but may also extend to other 
potentially relevant factors. (2) The algorithmic multiple 
criteria decision analysis (MCDA) approach defines criteria 
specifically for the intervention being appraised to construct 
an MCDA model. Stakeholders’ preferences are collected 
across criteria and value functions are constructed (usually 
by analysts) for measuring the intervention’s performance 
with respect to each criterion. The committee’s deliberation 
focuses on interpreting the MCDA model and its outputs 
and may take other factors into account qualitatively. (3) The 
reflective multicriteria approach proposes a generic decision 
criteria set, derived from the goals of health systems (which 
can be formulated as meeting individual patient needs, 
serving the whole population equitably, and ensuring financial 
sustainability32) as well as the principle that decision-making 
should be informed by best knowledge and understanding of 
the context.31 (Additional health system goals may include 
responsiveness to legitimate expectations of the population 
as well as fair financing57). Committee members’ deliberation 
involves judging the intervention’s performance on each 
criterion (qualitatively or quantitatively) and reflecting on the 
relative importance of the criteria.
For each feature, an option on how it could be addressed 
was specified within the LEM for each of these archetypes. 
Some of these options are inherent to an archetype, while 
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others are not; to stimulate discussion during the panel 
session, the non-inherent options were specified in a way that 
would differentiate between the approaches represented by 
the three archetypes. 
Specificities related to RDs and RTs pertaining to HTA 
and coverage decision-making were also identified for each 
feature (as applicable) (informed by the key literature,25,35,36,58,59 
see Appendix 2 for search terms) and included in the LEM to 
support reflection on the responsiveness of coverage decision-
making processes to the unique issues raised by RDs and RTs.
Panel: Recruitment, Session, Data Collection
Panelists were invited to a half-day face-to-face session in 
Rome, Italy, in June 2017. Panelists were identified and invited 
based on their experience and expertise in shaping HTA 
processes and their interest in and contribution to exploring 
the role of values, ethics and multicriteria approaches in 
coverage and reimbursement decision-making. Intending 
to include perspectives from diverse health systems, ten 
though leaders from 9 countries across Europe, North and 
South America were invited to participate. Seven of them, 1 
each from France, Germany, the Netherlands, Spain, and the 
United Kingdom, and 2 from Italy, agreed to participate in 
this study. Note that all 7 panelists are co-authors of this study 
(PA, BA, PK, LM, ASS, MS, and MT). Their fields of expertise 
encompassed (among others) medicine, health services 
research, health economics, health outcomes research and 
HTA and their current or past roles practicing clinician, 
journal editor, coverage decision-maker, and HTA process 
designer and administrator.
Panelists received the panel manual, containing the LEM, 
prior to the session. During the session, panelists were first 
presented with the LEM methodology. Then, each feature was 
presented and discussed in the group, followed by the panelists 
recording their individual inputs in writing. To encourage 
openness of discussion and free exchange of ideas, the session 
was conducted under the Chatham House Rule so that the 
comments made cannot be attributed to any individual.60 No 
consensus seeking was attempted. The session was recorded. 
Completed panel manuals were collected immediately 
following the session (some panelist completed part of their 
manuals after the session, which were then collected per 
email). 
Data Analysis
The written responses provided by the seven panelists in 
the manuals were the primary data sources. In addition, 
transcripts of the oral comments of the panelists during the 
session were also reviewed and used to clarify the meaning of 
the written inputs in order to ensure a correct understanding 
and representation of the overall flow and emphasis of the 
discussion. The panelists’ responses were analyzed using a 
thematic analysis approach (see details in Appendix 4). The 
features developed in the LEM were instrumental in our 
thematic data analysis. In a first step, panelists’ responses 
were organized by the LEM feature to which they pertained 
in tabular format. In a second step, within each feature, 
respondents’ accounts that involved convergent ideas or 
similar recommendations were identified and combined into 
one theme, in such a way that preserved the key elements of 
the original wording of the responses. (The 4 tables in the 
Results section present these synthesized themes for each 
A4R condition and feature). Responses to questions about 
whether a specific decision criterion should be considered 
and why were analyzed in the same manner; in addition, with 
respect to the closed parts of these questions, these responses 
were also categorized as positive (Yes), negative (No) or 
neither of these (Not specified). These were then counted to 
provide an estimate of the degree of convergence/divergence 
of the panel on that particular question. The results of the 
data analysis were provided to the panelists for their review 
and confirmation.
Results
The synthesized panelist recommendations for each A4R 
condition (and within this, each feature of the LEM) are listed 
in Tables 1 to 4 and are described below.
A4R Condition Relevance
Features Related to Participation in Decision-Making
Regarding the feature Facilitating participation in the committee 
of decision-makers that represent diverse perspectives, panelists 
raised the question of who is entitled to participate and 
highlighted the need for a clear definition of the roles of each 
stakeholder as well as extent and form of participation (Table 1).
The general view was that, while legitimacy requires 
involvement of all stakeholders, the final decision (in a 
primarily publicly funded health system) rests within the 
elected decision maker (ie, governmental authorities). 
The reflective multicriteria approach was specifically 
recommended to facilitate participation, particularly for RD 
decision-making, where participation of patients was seen as 
a critical element. To promote understanding and ensure that 
all voices are heard, it was advised to provide well synthesized 
data and strive to reduce “charisma issues” in the committee. 
Representative participation during the process of evidence 
generation—ie, not only in evidence appraisal—was also 
recommended.
Features Related to Decision Criteria
Panelists offered diverse views on who should be involved 
in Criteria selection, with a trend towards opening the 
process to the wider public and engaging all stakeholders 
(Table 1). There was also an emphasis on the importance of 
reflection about how the criteria can be rooted in the legal/
constitutional framework, goals of healthcare, social norms 
and overall population values and preferences. Diverse views 
were expressed regarding the consistency of decision criteria: 
some panelists stressed that consistency is a pre-requisite of 
accountability and legitimacy (and there should not be major 
differences between rare and more common diseases), others 
advocated for a more tailor-made, flexible approach to criteria 
selection, especially with respect to RDs and RTs.
Among decision criteria related to the Effect of intervention, 
there was consensus on the importance of Comparative 
effectiveness, which was viewed as the cornerstone of the 
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Table 1. Panel Recommendations With Respect to A4R Condition 1: Relevance
Feature What Could Be Recommended for This Feature in General? What Could Be Recommended for This Feature With Regard to 
RDs and RTs Specifically?
Facilitating 
participation in the 
committee of decision-
makers that represent 
diverse perspectives 
What could be recommended to facilitate participation of diverse perspectives (eg, patients, healthcare professionals, administrators, 
citizens)?
Multicriteria reflective approach best to facilitate participation; cost/QALY and algorithmic MCDA may not be fully applicable in all cases
Define form/extent of participation: providing substantive input (ie, empirical evidence), interpreting results, or deliberating as equal 
partners? 
Who is entitled to participate? How to guarantee that all participants are able to properly process the technical/scientific information?
Prior stakeholder engagement to develop common understanding, clear definition of roles and expectations
Direct the committee clearly and reduce charisma issues. Provide good-quality synthetized information before committee meeting
Ensure representation and participation also during the process of evidence generation
• In RDs, patients likely to be the best experts in their 
disease (do not have the same view as clinicians); reflective 
multicriteria the only way forward if the decision is to be 
legitimate
• Legitimacy requires involvement of all stakeholders, but final 
decision is with the Ministry of Health
Features Related to Criteria
Criteria selection 
process
What could be recommended regarding who should select the criteria?
Political decision (elected governments)
Decision-making committee
Public deliberation and majority voting in line with constitution and applicable laws
Institution with broad consultation (including workshops) of all stakeholders (eg, specialists, patient associations, patients, economists) 
Establish rules for weighting the importance of criteria (measuring criteria weights)
Flexibility (open to re-visit criteria set)
Accept the values obtained or construct the values?
What could be recommended regarding overall goal/values from which criteria are derived?
Typically derived from a nation’s constitution
Deliberation about the actual goals that underlie decisions
Overall population health values; these may be in conflict of the interests of specific groups 
They should reflect social norms and preferences elicited from the population
Should there be consistency of criteria across decisions?
Consistency is a pre-requisite for accountability and legitimacy and is crucial to insure equity across disease areas
Not necessarily; transparency of the criteria and their weights is more important
Yes, but we need a general generic framework that is flexible enough to adjust to specific issues
• Aim for in-depth understanding of how the actual decision 
is rooted in the fundamental goals of healthcare (eg, allow 
stakeholders to observe other decision processes)
• Adaptation to RDs: impact of number of patients and 
chronicity of the disease on the evaluation
• If we design a system for dealing with all interventions 
(including RDs and RTs), we may create procedures that are 
inefficient for many of them 
• Same rules for all technologies: humanistic; clinical, economic 
criteria
• No major difference to common diseases
Generic Criteria and Rationales (ie, criteria are used across decisions)
Domain: Effect of intervention
Comparative 
effectiveness
Should the comparative effectiveness of the proposed intervention be considered and why?
- Yes (7/7)
Comparative effectiveness is the cornerstone of decisions because it reflects the type and extent of effect for the patient, which is directly 
rooted in the goal of the healthcare system 
Need to justify the choice of comparator
Problem of defining a common “health gain” measure across diseases
• Assessment of orphan drugs needs adaptation (eg, use of 
lesser quality data) due to lack of comparators and (in a first 
step) use of intermediate rather than final outcomes
• Requirements for proof of clinical effectiveness should not be 
relaxed, not even for ultra-rare disorders
Wagner et al
International Journal of Health Policy and Management, 2019, 8(7), 424–443429
Type of benefit 
(eg, curative 
treatment, preventive 
intervention)
Should the nature of the clinical benefit provided by the proposed intervention (eg, symptom relief, life extension, cure, prevention) be 
considered and why?
- Yes (4/7, 1 no, 2 not specified)
Yes, offers space for value claims; patient perspective may differ by type of benefit
Prevents programs from prioritizing only one kind of benefit; need to distinguish between preventive and curative benefits because 
prevention can have collective benefit 
Important for coverage decisions; however, difficult or infeasible to rank. Prioritization of quality over quantity of life (or vice versa) should 
be backed by specific evidence
No need to differentiate between types of benefit; effect on outcomes captures this concept
• RD patients are the only judges of their condition
• Might prove infeasible for coverage decisions
• Type of benefit may not be known at time of decision (eg, 
gene therapy may possibly cure a disease but needs long-term 
evaluation)
Safety/tolerability Should the safety/tolerability of the proposed intervention in relation to alternatives be considered and why?
- Yes (6/7, 1 no)
Only tolerability known at the time of decision, safety data comes only after drug is used in clinical practice
Important part of the decision
No, safety/tolerability  should be established prior to reimbursement decisions
• In RDs with few and small randomized controlled trials 
patients could accept higher risks
• Pharmacovigilance not helpful in RD and RT setting
• Nothing specific
Patient-perceived 
health/PRO 
Should patient-perceived health/PRO generated by the proposed intervention in relation to alternatives be considered and why?
- Yes (7/7)
Yes, otherwise only life-extending interventions would be developed 
Yes, always, even if data is less frequently available. Patients’ assessment of their own outcomes should be an integral element of the 
evidence for a therapy 
Advantage of QALY: cross-disease comparability, but disease-specific measures better to capture treatment effect
Yes, but apply the same documentation standards as for clinical endpoints 
• Individual changes in PRO levels are more important than 
absolute PRO levels
• Inclusion of disease-specific PRO instruments in clinical trials 
will require their validation, which is, however, not feasible 
prior to the trial
• Nothing specific
Intervention-specific 
(eg, disease-specific 
outcomes)
How should intervention-specific criteria be included and why? (eg, outcomes) 
Intervention-specific outcomes are crucial to assess efficacy
Important to determine disease-specific outcome measures and make them comparable (harmonization), but this may not always be 
feasible
• RD and RTs are very context-specific; may need specific 
criteria
• Identify information needs for RDs
Domain: Disease severity and unmet needs
Availability of 
alternatives (unmet 
needs)
Are the availability of alternatives and their shortcomings in their safety/tolerability or in their ability to prevent, cure, or improve the 
targeted health condition or ameliorate patient-perceived health considered and why?
- Yes (4/7, 1 no, 1 not specified, 1 no data)
Yes, but what can be seen as ‘alternatives’ needs to be defined
Yes, essential for evaluating the benefit of an intervention; reflects justifiable resource allocation
Yes, should be assessed as part of the comparative effectiveness domain
Considered in practice but not a robust decision criterion
• Comparators are often absent; can be challenging to define 
“usual care”
• Crucial for RDs
• Nothing specific
Feature What Could Be Recommended for This Feature in General? What Could Be Recommended for This Feature With Regard to 
RDs and RTs Specifically?
Table 1. Continued
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Disease severity Should the severity of the targeted health condition with respect to mortality, morbidity, disability, impact on function and quality of life, and 
clinical course be considered and why?
- Yes (5/7, 1 no, 1 not specified)
Yes, raises awareness of the goal of decision-making
A major point. There is social consensus that the most severely affected people should be treated first. Overwhelming empirical evidence for 
a strong public preference, backed up by normative considerations
Operationalization of this criterion requires a metric to measure severity. Priority conditions should be defined on a collective level
Linked to ‘Type of benefit.’ Disease severity is irrelevant when considering marginal benefits
• RDs are often severe
• Nothing specific
Domain: Economics
Cost (price) of 
intervention 
Should the cost (price) of the proposed intervention (includes acquisition and administration) in relation to current alternatives be considered 
and why?
- Yes (5/7, 2 not specified)
Crucial for healthcare system sustainability and for value-based use of resources
The cost itself is essential, not just the incremental cost in relation to alternatives
Although price considerations are out of scope of HTA, inclusion of costs in HTAs informs opportunity cost considerations 
Yes, Consider also that payers and insured taxpayers/health plan members may have different perspectives
Budget impact is important
• Remember that costs for “personalized/precision medicine” 
are paid for by society’s solidary
• Expenses for RDs are becoming too large; need new 
(collaborative) ways of developing treatments 
• Need to look at costs as a lifetime approach
• High cost, but budget impact acceptable from a political point 
of view
• Role of rarity needs to supported by further empirical studies. 
Depending on the type of intervention and its underlying 
economics, there could be specific considerations with 
respect to RDs
Consequences of 
intervention for other 
medical costs
Should the impact of the proposed intervention on other medical costs (apart from interventions that are directly replaced) be considered 
and why?
- Yes (5/7, 1 not specified, 1 no data)
Yes, clarifies the value proposition and opportunity costs; reflects general principles of health economics
Although logical to include, problem of “silo” budgeting limits the consideration of other medical costs
Less important than direct costs (should be just explored, depending on what these costs are); maybe important for innovative therapies 
• Other medical costs often negligible compared to the cost of 
therapy
Consequences of 
intervention for non-
medical costs 
Should the impact of the proposed intervention on non-medical costs (eg, lost productivity, care giver time, social services, disability costs) be 
considered and why?
- Yes (4/7, 1 no, 1 not specified, 1 no data)
Generally not considered but should be in principal
Relevant from the perspective of patients and families
Less important than direct costs but can be explored
In public-payer systems, probably unreasonable to include costs that are not covered by the public payer
• Should be considered but often negligible compared to 
treatment costs
• Much more important for conditions with high disability
Budget impact, 
affordability and 
opportunity costs
Should the budget impact, affordability and the opportunity cost of the proposed intervention be considered and why?
- Yes (6/7, 1 no data)
Affordability is becoming more and more important; opportunity cost always to be considered
Yes, budget impact reflects a change in focus from individual patient costs to program costs
• Despite low number of patients, budget impact can be 
significant
• Any RD specificities can be reflected by the program costs 
approach (ie, budget impact) and social cost value analysis
Feature What Could Be Recommended for This Feature in General? What Could Be Recommended for This Feature With Regard to 
RDs and RTs Specifically?
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 ICER Should the incremental cost-effectiveness ratio of the proposed intervention be considered and why?
- Yes (4/7, 1 no, 2 not specified)
ICER must be placed in context of other attributes of the disease/patient/treatment
Although necessary to provide, does not afford appropriate information for decision-makers
ICER is important to inform and document the decisions
No, that would amount to double-counting in an MCDA framework
May be used to examine whether added benefits justify added costs when comparing interventions targeting the same condition (ie, 
productive efficiency). Should not be used to inform allocative efficiency/opportunity cost considerations across disease areas
When there is no mortality impact, use cost-effectiveness (eg, cost per event avoided) rather than cost-utility because it has a real-world 
meaning to decision-makers
• ICER not very informative. Regulators and reimbursement 
committees treat RDs differently 
• Serious methodological flaws for decision-making in RDs and 
RTs
• Difficult to apply; may be used to “justify” high price 
• Never use for RDs
Domain: Ethical, social and legal aspects
Rarity/Size of affected 
population
Should the rarity of the condition and/or the size of the population targeted by the proposed intervention be considered and why?
- Rarity: Yes-No (3 yes, 3 no, 1 not specified); Size of population: 1 yes, 6 not specified
Yes, rarity is usually considered
No, rarity by itself not meaningful without relation to other aspects, such as severity, budget impact,  complexity of care
Small population requires a different approach to assessment; MCDA more pertinent
Rarity is problematic and difficult. Danger that this concept could be misused to justify higher prices
No, but consider a separate budget dedicated to RDs
Yes, if cost/patient or cost/QALY (rather than budget impact) are used as benchmarks
• A designated fund for RD and RT therapies would make this a 
different kind of decision, but do societies prioritize specific 
services to specific populations?
• Rarity should not be used to ask for high price but could 
suggest distinctive financing (payment) pathways
Prioritized populations Should prioritization of specific populations (eg, vulnerable populations), as defined by policy decision-makers/societies, be considered and 
why?
- Yes-No (2 yes, 1 no, 4 not specified)
Depends on history, beliefs and political environment
Yes, but priorities should be set and discussed publicly 
Always considered; better to make this explicit
Strictly political question, outside of analysis of costs and benefits
Priorities should be captured through formal analysis (ie, social cost value analysis)
• RD patients usually prioritized; severity and age play a crucial 
role (‘vertical equity’)
• RDs and RTs should not compete with other interventions; 
need a separate evaluation process
Feasibility of 
implementing 
intervention
Should the capacity of the healthcare system to appropriately implement the proposed intervention with respect to infrastructure, 
organization, skills, legislation requirements etc. be considered and why?
- Yes (6/7, 1 no)
Yes, essential but never properly assessed. Need to ensure that potential benefits are realized in clinical practice. This is an input but also an 
output of the evaluation (recommendation)
Define reference centers of excellence for innovative treatments 
Not as part of the initial evaluation,  but important when it comes to implementation
• Very important for RDs: need to recognize implementation 
hurdles
• Ultra-RDs can have very specific procedures; care often 
delivered at tertiary referral centers
Political, historical and 
cultural considerations
Should the political, historical and cultural context be considered and why?
- Yes-No (No 3/7, 2 yes, 1 not specified, 1 no data)
No, we need a systematic approach; nevertheless, in practice highly influential and inevitable 
Can provide important insights and adds value for collective learning in decision-making
Should only be considered informally (qualitative approach); maybe a checklist to identify patient barriers
• Issues more pronounced 
Feature What Could Be Recommended for This Feature in General? What Could Be Recommended for This Feature With Regard to 
RDs and RTs Specifically?
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Innovative-ness Should the concept of innovation be considered and why?
- No (5/7, 1 yes, 1 not specified)
No, the meaningful aspects of innovation (‘making a difference’) are already covered by other criteria
How to define and fund ‘innovation’? How to control its spread?
Audit new therapies to see how they perform in practice in order to enhance learning and support best and proven innovations
In principle, yes, as it relates to dynamic efficiency
• Innovation is the rule in these therapeutic areas
Uncertainty of evidence
Degree of uncertainty 
related to evidence 
(quality of evidence)
Should the relevance and validity of the evidence supporting the proposed intervention as well as the degree of uncertainty related to this 
evidence be considered and why?
- Yes (Yes 5/7, 2 not specified)
Sophisticated algorithmic methods might not be helpful
Real-world evidence contributes little to reducing uncertainty because of problems with validation 
Uncertainty should be distinguished from quality of evidence
Improving ‘uncertainty’ does not necessarily lead to better decisions
Yes, assessment should include effect size and degree of confidence
• Uncertainty should be placed in the context of rarity: typically, 
small samples show large effects but low precision. Accept 
lower-quality data than usually required
• Important to separate uncertainty from the magnitude of the 
measured effect 
• Real-world evidence needed to evaluate long-term benefit of 
RDs and RTs
• Higher uncertainty can only be accepted temporarily
Features Related to Evidence
Considering different 
types of evidence 
What type of evidence should be considered: scientific, colloquial (“anything that that establishes a fact or gives reason for believing 
something”7) imputed by logic, insights/ experiential?
For some parameters, scientific evidence is needed, for others colloquial, but relevance must be justified 
randomized controlled trials do not address clinically relevant questions; therefore need expert evidence
Any kind of evidence, but hierarchy: scientific, social “science,” expert opinion; keep them separate in assessment but consider jointly in 
appraisal
Apply principles of evidence-based medicine within a pre-specified decision-making structure; allowing anything is likely to obscure rather 
than inform
• Most important for RDs
• For RTs and RDs moving towards more “open concept” of 
providing evidence
Selection of evidence What should drive the selection of evidence to be included in the assessment?
Relevance to the question at hand; relevance needs be justified 
Scientific robustness is important, but there are also other elements
Not only systematic review; allow any stakeholder to suggest evidence
• Include all relevant evidence
Presentation of 
evidence 
How should the evidence be presented to enhance clarity and support deliberation? 
Synthesized evidence and criteria side-by side (“by-criterion report”), key points in Executive Summary. Need to include uncertainty on 
evidence for each criterion 
Systematic review style; discuss strengths and weaknesses of evidence base
Need transparency about what is known and unknown (data gaps) 
• Transparency also about uncertainty
Feature What Could Be Recommended for This Feature in General? What Could Be Recommended for This Feature With Regard to 
RDs and RTs Specifically?
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Balancing values at 
stake 
How should the values at stake be balanced during the deliberation? 
Committee composition has to reflect the different values that exist in society
Balancing values should remain a discursive task: weighting should inform and structure deliberations not replace them. To ensure 
legitimacy and transparency, deliberations must be well documented
Who should balance the values at stake? 
Decision-makers, typically politicians
Diverse stakeholders should deliberate to identify which/whose values are at stake. A compromise must eventually be made, based on well-
documented deliberations
Stakeholders should bring their own values
• NA
Assessing the 
performance of the 
intervention* 
How should the performance of the intervention be assessed?
Empirical testing
Based on its real-world impact 
Who should be assessing the performance? 
HTA units or researchers, but design of assessment must be in advance agreed upon between researchers and the committee 
Independent appraisal committee with representation from all stakeholder groups
• NA
Including individual 
interpretations 
to reach a group 
equilibrium in 
formulating a decision 
How should individual interpretations be included/shared to reach a group equilibrium in formulating a decision? (eg, consensus, vote)
If consensus can initially not be reached, give additional time for reflection. Committee members should be convinced that changing their 
minds is not a sign of weakness but of learning and reflection
Voting if consensus cannot be reached
• NA
Decision rules and 
uncertainty
Should there be decision rules to guide the decision-making? What should they be? 
Decision rules can enhance transparency. If used, they should support and not replace deliberation and decision-making. They need to be 
well justified 
Multicriteria approaches will need some sort of a threshold, but rooted in deep reflection on priority setting and the goals of the healthcare 
system and on opportunity costs
How should uncertainty in decision-making be handled?
Sophisticated tools for quantifying uncertainties (eg, value of information analysis) may be of limited use in actual decision-making
• ICER threshold may prove legally and politically  unfeasible
Abbreviations: A4R, accountability for reasonableness; QALY, quality-adjusted life-year; MCDA, multiple criteria decision analysis; RD, rare disease; RT, regenerative therapy; PRO, patient-reported outcomes; ICER, Incremental cost-
effectiveness ratio; HTA, health technology assessment.
* NOTE: In this context, performance is defined as how good an intervention is in regard to a specific decision criterion (eg, highly efficacious = high performance with regard to efficacy).
Feature What Could Be Recommended for This Feature in General? What Could Be Recommended for This Feature With Regard to 
RDs and RTs Specifically?
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decision and directly rooted in the goal of healthcare (Table 1). 
Definition of a common health gain measure across diseases 
was raised as a general challenge. Additional challenges, 
specifically with respect to RD interventions, included 
comparator selection in therapeutic areas where the standard 
of care is palliation only, and the use of intermediate outcomes. 
These factors may, according to some but not all panelists, 
require adaption of assessment methods to RD specificities. 
Panelists agreed that Patient-perceived health/patient-reported 
outcomes (PRO) should always be considered; however, it 
was recommended that the same documentation standards 
should apply as with clinical endpoints. Panelists confirmed 
the value of both generic and disease-specific PRO measures. 
With respect to RDs, however, they highlighted the difficulty 
of validating disease-specific PRO instruments in the RD 
setting. While the majority (6/7) regarded Safety/tolerability 
as an important aspect of the coverage decision, one view 
was that this belongs to the realm of regulatory decision-
making. Panelists also noted the lack of safety data at the time 
of the reimbursement decision. In the RD and RT settings, 
pharmacovigilance was deemed of limited usefulness. Four of 
the 7 panelists thought that the criterion Type of benefit should 
also be considered because patients may view interventions 
differently depending on the type of benefit they provide and 
also to capture collective benefits from prevention. However, 
panelists also stressed the inherent difficulties in ranking 
different types of benefits (eg, life extension versus quality of 
life improvement). Also, they noted, specifically with respect 
to RTs and RDs, that the type of benefit may not be known 
at the time of the decision. Non-generic criteria, specific to 
an intervention (eg, disease-specific outcomes) should be 
clearly defined and ideally harmonized across assessments 
of different treatments for the same RD or RT. The latter, 
however, is not always feasible, particularly for interventions 
targeting RDs and RTs, which may have very specific outcome 
measures that may be tailored to the mode of delivery and the 
specific impact of the intervention.
Regarding the Disease severity and unmet needs domain, 
4 panelists recommended considering the Availability of 
alternatives (unmet needs), whereas one did not see this as 
a robust decision criterion (Table 1). Panelists raised the 
challenge of identifying the appropriate alternatives (or 
comparators), particularly for RD therapies. Consideration 
of Disease severity was also recommended by a majority of 
panelists (5/7), because it was perceived to raise awareness 
of the goal of healthcare and reflected broadly shared social 
values. However, panelists noted that proper consideration of 
Disease severity required a metric or ranking of conditions, 
which would need to be defined collectively within a society.
The Economics domain contained five criteria: Cost 
(price) of intervention; Consequences of intervention for other 
medical costs; Consequences of intervention for non-medical 
costs; Budget impact, affordability and opportunity costs; and 
incremental cost-effectiveness ratio (ICER) (Table 1). All of these 
aspects were recommended to be considered by a majority of 
panelists, with Budget impact, affordability and opportunity 
costs gaining the greatest support overall (6/7). Consideration 
of Cost (price) of intervention was deemed essential (5/7), as 
decision-makers aim to maintain health system sustainability 
and use resources based on the value provided, while taking 
opportunity costs into account. Panelists highlighted the high 
costs of RD and RT therapies and the ethical challenge that 
these “personalized medicines” pose to societies that strive to 
uphold the principle of solidarity. Panelists debated how to 
justify these high costs, whether or not they lead to significant 
budget impacts. One view was that there could be special 
considerations regarding the cost of RD interventions, related 
to their type and underlying economics, but these would need 
to be verified by further empirical studies. In this context, 
it was also noted that societies may place a value on not 
abandoning patients who suffer from rare, high-cost diseases, 
an element that could be integrated into value assessment, eg, 
through ‘social cost value analysis.’ One panelist also suggested 
that healthcare program costs (ie, budget impact) rather than 
the cost per patient would be the more appropriate approach 
to consider opportunity costs in the RD setting. 
Panelists tended to agree that considering the Consequences 
of intervention for other medical costs was logical (ie, “reflects 
general principles of health economics”) (5/7), but with 
respect to RDs and RTs it was noted with that these costs are 
often negligible compared to the costs of the therapy itself, 
except possibly for some highly innovative interventions that 
are able to obviate other therapies (Table 1). Consideration 
of Consequences of intervention for non-medical costs was 
viewed to be relevant from the perspective of patients and 
their families and important for diseases with high disability 
burden (4/7). However, an alternative view was that it may not 
be appropriate to consider costs that are not covered by the 
payer who is making the coverage decision. 
Consideration of the ICER was found to be useful to inform 
decisions by a majority (4/7), as it related added benefits to 
added costs (Table 1). Although cost-effectiveness analysis was 
deemed applicable for comparing interventions that target the 
same disease, the validity of setting universal ICER thresholds 
to inform allocative efficiency/opportunity cost decisions 
across disease areas was challenged by several panelists. In 
this context, it was recommended to avoid using the cost-per-
QALY ratio for treatments that have no mortality impact, and 
rather relate costs to specific outcomes (eg, events), which are 
more meaningful to decision-makers. One panelist pointed 
out that the use of the ICER as a criterion within an MCDA 
framework that also contained effectiveness and cost criteria 
should be avoided as it would amount to double-counting. 
The use of the ICER in the realm of RDs and RTs was generally 
viewed as problematic due to methodological difficulties (ie, 
small sample size) and the fundamental challenge of universal 
ICER thresholds (as mentioned above). The caveat that the 
ICER threshold may be used to justify high prices (ie, to 
raise prices to just below the ICER ceiling) was also raised, 
specifically in relation to RD/RT interventions.
Among criteria of the domain Ethical, social and legal aspects, 
considering the Feasibility of implementing intervention was 
deemed essential by most panelists (6/7) in order to ensure 
that potential benefits are realized in clinical practice (Table 1). 
This was found to have particular importance for RD therapies, 
eg, because some of them need to be delivered in tertiary 
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referral centers. However, with respect to Innovativeness, the 
majority view (5/7) was that it should not be considered, as 
all meaningful aspects of innovation (‘making a difference’) 
are already covered by other criteria. A dissenting view was 
that innovativeness should, in principle, be considered in 
relation to dynamic efficiency, ie, the benefits gained over the 
longer term through investment in innovation. Panelists also 
offered diverse views on Rarity/Size of affected population and 
using rarity for Prioritizing populations. One view was that 
rarity should not be considered in isolation but in relation 
with other aspects, such as disease severity and complexity 
of care. Some raised also the point that the concept of rarity 
may be misused to justify higher prices. Others expressed 
that rarity is often considered distinctively in practice and 
called for an MCDA-based approach to evaluating RD 
interventions. A further view was that if RDs and RTs are 
indeed societal priorities, then dedicated sources of funding 
could be established. With respect to Prioritized populations, 
in general, panelists recommended that prioritizations should 
be aligned with the values of society through broader public 
engagement and should be incorporated into evaluations 
explicitly and systematically. Political, historical and cultural 
considerations can in practice be important, but should, if 
included in a decision-making framework, be considered in 
a qualitative approach. 
A majority of panelists (5/7) recommended considering the 
Degree of uncertainty related to evidence (quality of evidence) 
(Table 1). Specific recommendations included to distinguish 
effect size from its (un-)certainty and to treat quality of 
evidence (ie, its relevance and validity) as a separate notion 
from ‘uncertainty.’ With respect to RDs, one view was that, 
because of smaller samples sizes, less stringent data quality 
requirements could be used; others, however, contended that 
uncertainty can only be accepted provisionally and needs to 
be addressed by generating reliable (real-world) evidence 
effectiveness, eg, in the context of conditional access schemes. 
Features Related to Evidence
With respect to Considering different types of evidence, several 
panelists expressed the view that both scientific and colloquial 
evidence (eg, expert evidence) is needed, particularly with 
respect to RTs and RDs, but with justification and related 
to the parameter in question (Table 1). However, there was 
also the caveat that “allowing anything is likely to obscure 
rather than inform.” Selection of evidence should be driven by 
scientific robustness and also by its relevance to the question it 
is supposed to address. Recommendations on how to Present 
evidence to enhance and support deliberation included 
presenting synthesized evidence for each decision criterion 
in a ‘by-criterion report’ or to use a ‘systematic review style.’ 
Panelists generally stressed the need to be transparent about 
the strengths, weaknesses and gaps of the evidence. 
Features Related to Deliberation
Regarding Balancing the values at stake, several panelists 
stressed the need to ensure that the diversity of values held 
by society is included in the decision-making committee’s 
deliberation, although the role of elected government 
representatives was also highlighted (Table 1). Explicitly 
assigning weights to these values could help inform and 
structure the deliberation; however, weighting should aim 
to support, not replace, the collective thinking and learning 
process, which must arrive at a compromise in balancing 
the diversity of values. With respect to the feature Assessing 
the performance of the intervention, panelists commented 
that effectiveness should be assessed based on real-world 
impact and performed by HTA experts using a methodology 
formerly endorsed by the committee, or alternatively, by the 
members of the committee themselves with participation of 
diverse stakeholders. With respect to Including individual 
interpretations to reach a group equilibrium in formulating 
a decision, panelists recommended to provide ample room 
for reflection in order to foster openness and discourage 
defensiveness. Decision rules are needed for the sake of 
transparency; however, they should be grounded “in deep 
reflection on priority setting and the goals of the health 
system and on opportunity costs” and not be used in a rigid 
algorithmic fashion. With respect to RD and RTs, one panelist 
stated that firmly sticking to the ICER threshold may prove 
legally and politically infeasible.
A4R Condition 2: Publicity
Three features were defined to operationalize the publicity 
condition: Transparency of criteria, evidence and approaches 
used to consider them, Understandability of reasoning behind 
the decision, and Clarity of values underlying the decision 
(Table 2). In general, panelists recommended transparency 
about the evidence and methods used in the assessment 
as well as transparency about the values that underlie the 
decision. Specifically, it was recommended to make explicit 
the value judgments used in the process of generating 
and selecting evidence, to communicate honestly and 
understandably to the public (including the uncertainties 
involved in the decision), and to clarify the relative weights 
of the decision criteria used. Additional attention should 
be paid to justifying endpoint selection for RD and RT 
interventions. Furthermore, one panelist stressed the need to 
further develop and professionalize the art of documenting 
and public communication about the decision, particularly in 
view of difficult decisions for RDs and RTs.
A4R Condition 3: Appeal and Revision
The third A4R condition was operationalized through two 
features: Handling of disagreements from stakeholders, thus 
addressing appeals, and Handling new evidence or new context, 
addressing revisions (Table 3).
With respect to Handling of disagreements from stakeholders, 
panelists recommended involvement of diverse stakeholders 
in the process as well as a high level of transparency and 
publicity, which includes explicit decision rules, public 
debates, and providing space for dissenting voices to be heard, 
such as by publishing minority reports (ie, separate report 
prepared by a group representing a numerical minority of a 
committee) (Table 3). With respect to Handling new evidence 
or new context, recommendations included establishing clear 
rules regarding reviews, which should include a definition of 
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Table 2. A4R Condition 2: Publicity
Feature What Could Be Recommended for This Feature in General? What Could Be Recommended for This Feature 
With Regard to RDs and RTs Specifically?
Transparency of criteria and 
evidence considered and 
approaches used to consider 
them
Should the evidence that was considered and the methods to select and synthesize the evidence be made public? 
•	 Yes, always and unconditionally
•	 Yes, should be described adequately and justified meticulously (including all value judgments used in the process of generating and 
selecting evidence), then made public
Should the criteria and the deliberative approach to consider them be made public?
•	 Yes, deliberations and advice published on the website of the HTA agency
•	 Protect individuals according to Chatham House Rule
•	 Additional attention to justifying the 
selected endpoints
Understandability of 
reasoning behind decision
What could be recommended to facilitate making reasons leading to the decision explicit and understandable to stakeholders, including the 
public?
•	 Keep it simple and understandable. The art of good documentation and communication needs to be more valued and further 
developed 
•	 Communicate honestly about uncertainties and imperfection of decisions
•	 Include a natural language account of the process, the key evidence used and the facts 
•	 Knowledge brokers and health 
anthropologists can play an 
important role. Avoid emotion-
laden communications, which are 
counterproductive for legitimizing 
decisions
Clarity of values underlying 
the decision
Should values underlying decisions be stated? Should there be a reference to the broader objectives and underlying mandate of the agency/
institution/healthcare system?
•	 Yes, generally. Also, the extent to which the intervention contributes to or infringes upon the mandate of the healthcare system and 
broader societal objectives must become explicit
•	 Clarify the weights of the different criteria in the final decision
•	 Public health impact is generally low in 
RDs, we have to address the fact that 
incidence and prevalence are low
Abbreviations: A4R, accountability for reasonableness; RD, rare disease; RT, regenerative therapy; HTA, health technology assessment.
Table 3. A4R Condition 2: Appeal and Revision
Feature What Could Be Recommended for This Feature in General? What Could Be Recommended for This Feature With Regard to 
RDs and RTs Specifically?
Handling of 
potential 
disagreements 
from 
stakeholders
What could be recommended to facilitate consultation to collect feedback from stakeholders on interpretation of data, rationale for decision, values 
considered and/or reduce the need for appeal? 
•	 Inclusion of different stakeholders in multi-lateral deliberation 
•	 Make decision-making rules explicit 
•	 Transparency and publicity of the debates
•	 Publish minority reports. Sponsor lay stakeholder rebuttal statements
•	 NA
Handling new 
evidence or new 
context
What could be recommended to facilitate considering new evidence or new context?
•	 Need a precise definition of ‘new evidence’ 
•	 Publish rules regarding appeals and reviews, including fixed review dates. However, allow for fast-track recall/review in case of  
emergence of pivotal new evidence
•	 Communicate that decisions are provisional and will be updated according to evidence 
•	 Consider CED
•	 CED important for RDs and RTs. This should involve 
active and constant improvement of the evidence 
generation framework
•	 Evidence generation and documentation of clinical 
outcomes are needed. Performance contracts are useful 
in this situation
Abbreviations: A4R, accountability for reasonableness; RD, rare disease; RT, regenerative therapy; CED, coverage with evidence development.
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what would qualify as ‘new evidence,’ and also allowing the 
considering new pertinent evidence in a timely fashion. For 
RDs and RTs specifically, continuous evidence generation 
and documentation through coverage with evidence 
development (CED) and performance-based contracting 
were recommended.
A4R Condition 4: Enforcement (or Implementation)
To ensure that all relevant criteria and evidence are 
considered in a deliberative process that is inclusive of diverse 
perspectives (enforcement of Condition 1 – Relevance), 
one recommendation was to implement external and 
independent quality reviews of final deliberations (Table 
4). Another recommendation was to ensure representative 
inclusion of different perspectives (ie, stakeholders, different 
scientific disciplines), which would be particularly well suited 
for deliberations regarding RDs and RTs (Table 4). A third 
recommendation was to create conditions in the committee 
that would promote deliberation and collective learning (eg, 
facilitated discussion by a skilled, independent moderator).
With respect to ensuring publicity of the decision rationales, 
ie, enforcement of Condition 2 – Publicity, visualization tools 
were mentioned as one means for ensuring that the reasons 
behind decisions are understandable and transparent and 
the values on which they are based are clear (Table 4). This 
includes the role and influence of MCDA criteria weights. 
Panelists again stressed the need for promoting a culture of 
collective learning among diverse stakeholders.
To ensure revisability of the decision in light of new evidence 
or arguments (enforcement of Condition 2 – Appeal and 
Revision), panelists recommended making re-assessments 
an integral part of the HTA process and highlighted the 
importance of proper documentation of decision rationales to 
support re-assessments (Table 4). Furthermore, the objective 
and timing of a planned re-evaluation should be clearly 
defined, so that relevant evidence can be planned for and 
generated (eg, in the context of CED) to address the pressing 
questions and evidence gaps. A final recommendation was to 
further develop HTA methodology by conducting conceptual 
and empirical research on multicriteria decision-making 
approaches. These recommendations were general but, 
according to one panelist, would primarily apply to RDs and 
RTs.
Discussion
In this study, we reflected on and collected recommendations 
on the features that would characterize a legitimate and 
fair healthcare coverage decision process, using A4R as a 
conceptual framework. 
A key recommendation for meeting the Relevance condition 
was to ground the criteria for healthcare coverage decisions in 
the legal/constitutional framework and normative (ethical) 
foundations. This requires reflection on the fundamental 
goals of healthcare, in the context of a country’s constitution, 
and how to transform these into operationalizable decision 
criteria.5,31 Decision criteria also need to be informed by a 
society’s values and preferences, which involves seeking to 
incorporate the priorities of citizens in decision-making 
(eg, through social cost value analysis), an area where there 
is a need for more robust evidence development.61 In this 
study, among a list of 17 generic decision criteria, 13 were 
recommended by more than half of the panelists, highlighting, 
as noted in previous research,62,63 the wide range of factors that 
could be considered relevant to coverage decision-making. 
For RDs, specifically, a broad perspective on value has been 
recommended64,65 and the use of a range of scientific and 
value judgements have been documented in actual coverage 
decision-making practice.66 
Although the majority of the panelists supported using some 
form of cost-effectiveness analysis to inform decision-making, 
the use of the cost-per-QALY ratio alone to allocate resources 
across the health system was challenged on methodological 
and ethical grounds, especially for interventions targeting 
RDs. Indeed, it has been previously claimed that failing to 
incorporate diverse ethical positions (eg, the rule of rescue, 
the rights-based approach, distributional justice/fairness 
considerations), this approach, which aims at maximizing 
the sum of QALYs across the population, may lead to 
prioritization decisions that are inconsistent with a society’s 
moral values.29,48,67 Cost-effectiveness ratios also do not 
provide information on affordability as the public provision 
of cost-effective interventions, may prove unaffordable for a 
health system.68 In addition, it has been argued on theoretical 
grounds that the cost-per-QALY threshold approach may fail 
to maximize health gain for a given amount of resources.69 
Furthermore, therapies targeting RDs, although their financial 
impact was shown to be and remain limited,70 often fail to 
meet cost-per-QALY thresholds,71 which may be viewed as 
disadvantaging patients with these conditions. This failure has 
generally been attributed to fixed R&D expenditures coupled 
with a small market size, which necessitate high unit costs, 
and the difficulty of generating high-quality comparative 
effectiveness evidence due the rarity of the condition.48 While 
the validity of these arguments must be further examined 
in empirical research,72 panelists tended to agree that rarity 
raises issues—related to unmet needs, constraints in evidence 
generation, and possibly in pricing (ie, return on investment 
from a smaller market)—which may warrant special 
consideration. However, they also noted that rarity should not 
be considered in isolation but in relation to other aspects such 
as disease severity, patients’ age, and budget impact. Indeed, 
surveys of the general population73-77 or medical doctors78 
do not support rareness per se as a prioritization criterion. 
Nevertheless, such surveys do frequently demonstrate 
agreement with the rights-based argument75 as well as a strong 
concern for fairness,73 and express support for prioritizing 
severe diseases that have high unmet needs,73,77 attributes that 
are characteristic of many rare conditions.79
Another key theme emerging from the recommendations 
was the importance of stakeholder involvement for legitimacy 
within the A4R framework. Abelson and colleagues provide 
a useful distinction within the term ‘stakeholder’ between 
the ‘public’ (ie, citizens who can broadly represent social 
values), ‘patients’ (ie, those who have experience with a 
specific technology or condition), and other stakeholders 
(ie, those with an organized interest in a technology or 
Wagner et al
International Journal of Health Policy and Management, 2019, 8(7), 424–443 438
Table 4. A4R Condition 4: Implementation (or Enforcement) 
Feature What Could Be Recommended for This Feature in General?
What Could Be Recommended for This 
Feature With Regard to RDs and RTs 
Specifically?
Existence of means to 
enforce condition 1 
What could be recommended to ensure that all relevant criteria and evidence are considered in a deliberative process that is inclusive of diverse perspectives?
•	 External and independent quality review of final deliberations by unconflicted third parties 
•	 Need to represent different stakeholders and all relevant disciplines (including, ethics, psychology, law, etc)
•	 Conditions for effective deliberation must be created and safeguarded (eg, skilled, independent moderator) to foster learning and prevent defensiveness 
•	 RDs and RTs well suited to pilot 
stakeholder deliberations
Existence of means to 
enforce condition 2
What could be recommended to ensure publicity of the rationales of the decision, ie, that the reasons behind decisions are understandable and the values on which they are 
based are clear?
•	 Use of visualization tools to clarify the rationale of the decision
•	 Promote a culture of collective learning among all stakeholders (including industry, payers, clinicians, patient organizations, etc)
•	 Linked to the weights of different domains underlying the decision
•	 NA
Existence of means to 
enforce condition 3 
What could be recommended to ensure revisability of the decision in light of new evidence or arguments?
•	 Need rules for integrating re-evaluation in pricing and reimbursement processes (‘life cycle’ approach)
•	 Development and piloting of CED arrangements 
•	 Define objective of the re-evaluation (new clinical outcome or outcome in real life) and evidence requirements to generate ‘relevant’ rather than ‘more’ 
evidence 
•	 Develop HTA methodology: both conceptual and empirical work on multicriteria decision-making 
•	 Need to ensure that reasons for a decision are properly documented to allow later re-assessment
•	 RDs and RTs are important 
areas for implementing these 
recommendations
Abbreviations: A4R, accountability for reasonableness; RD, rare disease; RT, regenerative therapy; CED, coverage with evidence development; HTA, health technology assessment.
.
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condition, such as providers, advocacy groups or industry).80 
Stakeholder involvement in HTA can occur at different 
levels: communication, which means receiving information 
on the assessment and its outcomes; consultation, which 
involves providing perspectives, experiences or preferences 
to inform the assessment; and participation, which means 
collaborating as partners in the assessment itself.80-82 In RDs, 
specifically, the crucial role of patients at all stages of evidence 
development has increasingly been recognized,83-85 resulting 
in calls for their active involvement in the HTA process as 
well.83 This was echoed in the panelists’ comments (“RD 
patients are likely to be the best experts in their disease”) 
and recommendations. The reflective multicriteria approach 
was specifically recommended to facilitate incorporation 
of diverse stakeholder perspectives, particularly that of 
patients in the RD and RT context. Previously, multicriteria 
methods were shown to be applicable for incorporating 
patients’ perspectives to inform priority setting86 and for value 
appraisal in the RD context.47,87,88 Participation of stakeholders 
with diverse perspectives serves to ensure that all potentially 
relevant reasons are examined in decision-making and to allow 
collective learning to take place during the deliberation.8,14 
This form of participation can potentially increase public 
trust in the decision and reduce the need for appeals. With 
respect to criteria selection, recommendations included 
conducting public deliberations and broad consultations 
to select and validate decision criteria, echoing the call for 
HTA agencies to “subject their decision-making criteria to 
public scrutiny by means of a democratic process.”14 Clearly, 
the specific purpose, type of stakeholder and level of public 
engagement (eg, consultation vs some form of participation) 
need to be clearly defined and the various models, proposed 
or implemented, further tested and evaluated in the legal 
and social context of specific health systems80,83,89 to ensure 
that these are effective and appropriate in enhancing the 
legitimacy of the decision-making process.
As clearly recognized and explicitly expressed in the 
panelists’ recommendations, diverse stakeholders may 
justifiably disagree on how to balance different, and often 
conflicting, decision goals. Therefore, creating conditions that 
foster deliberation is integral to legitimate decision-making. 
Deliberation is a form of learning that cannot be replaced 
through quantitative methods or the majority vote.8,39,41 It 
involves understanding the health intervention and one’s 
own values as well as sharing personal definitions, judgments 
and values (ie, ‘interpretive frames’) with others to question 
assumptions and engage in shared ethical reasoning.8,14 
Reflective multicriteria approaches can support this learning 
by providing a framework to structure the available evidence 
relevant to each decision criterion and to allow the explicit 
expression of values as separate from scientific judgments.5,14 
Additional panelists’ recommendations to support 
deliberation included:
•	 Providing good-quality synthetized information before 
the committee meeting;
•	 Having a skilled, independent moderator who is able to 
foster mutual learning, prevent defensiveness (“changing 
one’s mind should not be a sign of weakness”), and 
reduce the risk of dominant committee members from 
adversely controlling the course of the deliberation (ie, 
“reduce charisma issues”);
•	 Balancing values discursively; assigning numerical 
weights to decision criteria should inform and structure 
deliberations but not replace them;
•	 If consensus cannot initially be reached, providing 
additional time for reflection, or otherwise a practical 
compromise in order to meet the need for making 
decisions within a short timeframe.90 
Panelists also recommended being fully transparent about 
the weaknesses and uncertainties related to a decision (in 
addition to the methods employed and the underlying reasons) 
and as well as giving room to dissenting voices in order to 
foster an honest public debate, while creating conditions 
that promote the free exchange of ideas (eg, Chatham House 
Rule). In this regard, the art of effective and accurate public 
communication should be further developed, eg, through 
visualization tools. An additional recommendation was to 
reveal all value judgments used in the process of generating 
and selecting evidence. Indeed, previous research has drawn 
attention to the many and diverse types of value judgments 
that are implicit in the HTA process—including, for example, 
in selecting endpoints, defining thresholds for meaningful 
benefit, or performing specific types of economic analyses—
and recommended making these explicit to increase 
accountability and provide stakeholders the opportunity to 
fully participate in the discussion.91 Although a subject of 
debate,39,41 the extent and form of ethical analysis (ie, which 
of the many implied value judgments should be revealed and 
addressed) will need to be determined by what is relevant 
to the decision at hand,40 a question that could benefit from 
a structured multicriteria approach to evidence selection, 
synthesis and documentation. 
Ensuring that the relevance condition of A4R is met implies 
revisability of the decision in light of new evidence or new 
arguments. Regarding this aspect, panelists’ recommendations 
included CED and well-defined evidence needs and timelines 
for re-evaluation. These recommendations are echoed by 
a recent EURORDIS position statement that advocates for 
a rapid effectiveness assessment, which, while providing 
provisional access, would define a research question for 
targeted evidence generation to inform a full evaluation at a 
pre-specified point of time.65
Limitations
This work reports a reflection on a wide range of features 
of on how best to meet the A4R conditions for legitimacy 
in coverage decision-making processes, in general, and in 
the context of RD and RTs, specifically. This was an initial 
exploratory study; as this, there was, by design, no deliberate 
attempt to reach a consensus during the panel session, 
which may be seen as one limitation of this study. Thus, 
some recommendations may appear, at least on the surface, 
contradictory, because they were rooted in diverse often 
incommensurable considerations. Disagreements might have 
been resolved in the group given more time for reflection, 
clarification and communication. The study involved only 
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a relatively small group of panelists who were not intended 
to be representative of a wider HTA community, a particular 
jurisdiction, institution or approach. Panelists reflected on the 
questions posed and exchanged their insights based on their 
experience and expertise. A larger group of panelists may have 
provided a more diverse set of views and recommendations 
or, alternatively, may have revealed some areas of thematic 
convergence. The discussion of the panelists was supported by 
the LEM, which is not a coverage decision-making framework 
in itself, but a platform to elicit and structure reflection on 
the wide range of aspects that could operationalize the A4R 
conditions within the HTA context. While this study focused 
on HTA and health technology coverage decision-making, the 
A4R framework itself is meant to be applicable to limit-setting 
decisions in healthcare in general and some of the present 
findings may be useful for other applications within the 
health sector. Overlaps between different LEM features could 
have made this approach somehow cognitively demanding 
for the panelists. However, this is partly inevitable and reflects 
the interrelatedness of aspects in an actual decision-making 
setting. Conversely, the LEM may lack features that might be 
important. Not to be seen as a static tool, it can be further 
elaborated by the research community to foster the debate on 
how to address legitimacy requirements in decision-making. 
Conclusion 
Moving coverage decision-making processes towards 
enhanced A4R is a continuous effort that involves designing 
and refining approaches to support participation and 
multi-stakeholder deliberation, enhancing transparency, 
and defining decision criteria that reflect normative and 
societal objectives.5 RDs and RTs are an important area in 
which to spearhead these efforts. Reflective multicriteria 
approaches can support this endeavor by allowing the explicit 
consideration of the wide range of criteria that stakeholders 
may find relevant for a specific decision problem; facilitating 
stakeholder involvement (a particularly critical element 
for patients in the RD context); and providing a means for 
appraising scientific evidence, expressing diverse value 
perspectives and making value judgments explicit, which can 
be shared in committee deliberations. Further conceptual 
and empirical development of multicriteria approaches is 
warranted to support their application in accountable and 
reasonable decision-making.
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